MedTrace Logo

Appropriateness of Antibiotic Combination Therapy for Severe Community-acquired Pneumonia in South Korea

NCT06977347 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-05-18

No results posted yet for this study

Summary

This study aims to provide high-level evidence for appropriate empirical antibiotic use tailored to the clinical reality in Korea by conducting a randomized controlled trial comparing monotherapy with piperacillin/tazobactam and combination therapy with piperacillin/tazobactam plus a fluoroquinolone in patients with severe community-acquired pneumonia.

Conditions

  • Severe Community-acquired Pneumonia (sCAP)

Interventions

DRUG

Piperacillin/Tazobactam

Piperacillin/tazobactam: 4.5g IV q6h (over 3h)

DRUG

Piperacillin/tazobactam + Levofloxacin

Piperacillin/tazobactam: 4.5g IV q6h (over 3h) \+ Levofloxacin 750mg IV q24h (over 30min)

Sponsors & Collaborators

  • CHOSEOK YOON

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-15
Primary Completion
2026-12-31
Completion
2027-02-01

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06977347 on ClinicalTrials.gov